Masunaga Shin-Ichiro, Ono Koji, Kirihata Mitsunori, Takagaki Masao, Sakurai Yoshinori, Kinashi Yuko, Kobayashi Tooru, Suzuki Minoru, Nagata Kenji, Nagasawa Hideko, Uto Yoshihiro, Hori Hitoshi
Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Noda, Kumatori-cho, Sennan-gun, 590-0494, Osaka, Japan.
J Cancer Res Clin Oncol. 2003 Jan;129(1):21-8. doi: 10.1007/s00432-002-0397-3. Epub 2003 Jan 11.
We evaluated the potential of a newly developed (10)B-containing alpha-amino alcohol of p-boronophenylalanine-(10)B (BPA), p-boronophenylalaninol (BPAol), as a boron carrier in boron neutron capture therapy.
C57BL mice bearing EL4 tumors received 5-bromo-2'-deoxyuridine (BrdU) continuously via implanted mini-osmotic pumps to label all proliferating (P) cells. After oral administration of L-BPA or D-BPA, or intraperitoneal injection of L-BPAol or D-BPAol, the tumors were irradiated with reactor thermal neutron beams. Some of the tumors were heated at 40 degrees C for 30 min (mild temperature hyperthermia (MTH)) right before neutron exposure, and/or tirapazamine (TPZ) was intraperitoneally injected 30 min before irradiation. The tumors were then excised, minced, and trypsinized. The tumor cell suspensions thus obtained were incubated with cytochalasin-B (a cytokinesis blocker), and the micronucleus (MN) frequency in cells without BrdU labeling [ =quiescent (Q) cells] was determined using immunofluorescence staining for BrdU. Meanwhile, 6 h after irradiation, tumor cell suspensions obtained in the same manner were used for determining the apoptosis frequency in Q cells. The apoptosis and MN frequency in total (P+Q) tumor cells were determined from the tumors that were not pretreated with BrdU.
Without TPZ or MTH, L- and D-BPAol increased both frequencies markedly, especially for total cells. Although not significantly larger, L-BPA and D-BPAol increased both frequencies slightly more than D-BPA and L-BPAol, respectively. Combination with both MTH and TPZ markedly reduced the sensitivity difference between total and Q cells.
Both L- and D-BPAol have potential as a (10)B-carrier in neutron capture therapy, especially when combined with both MTH and TPZ.
我们评估了新开发的含(10)B的对硼苯丙氨酸 - (10)B(BPA)的α - 氨基醇,即对硼苯丙氨醇(BPAol)作为硼中子俘获疗法中硼载体的潜力。
携带EL4肿瘤的C57BL小鼠通过植入的微型渗透泵持续接受5 - 溴 - 2'-脱氧尿苷(BrdU)以标记所有增殖(P)细胞。口服L - BPA或D - BPA,或腹腔注射L - BPAol或D - BPAol后,用反应堆热中子束照射肿瘤。一些肿瘤在中子照射前于40℃加热30分钟(轻度温度热疗(MTH)),和/或在照射前30分钟腹腔注射替拉扎明(TPZ)。然后切除肿瘤,切碎并胰蛋白酶消化。将由此获得的肿瘤细胞悬液与细胞松弛素 - B(一种胞质分裂阻滞剂)一起孵育,并使用针对BrdU的免疫荧光染色确定未标记BrdU的细胞[=静止(Q)细胞]中的微核(MN)频率。同时,照射后6小时,以相同方式获得的肿瘤细胞悬液用于确定Q细胞中的凋亡频率。从未用BrdU预处理的肿瘤中确定总(P + Q)肿瘤细胞中的凋亡和MN频率。
在没有TPZ或MTH的情况下,L - 和D - BPAol均显著增加了这两种频率,尤其是对总细胞而言。虽然增加幅度不显著,但L - BPA和D - BPAol分别比D - BPA和L - BPAol略微更多地增加了这两种频率。与MTH和TPZ联合使用显著降低了总细胞和Q细胞之间的敏感性差异。
L - 和D - BPAol在中子俘获疗法中均有作为(10)B载体的潜力,特别是在与MTH和TPZ联合使用时。